News
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Astellas is investing around $70 million, providing lab and co-working spaces to support current and future growth initiatives in the cell and gene therapy space for cancer and rare diseases.
In a recent interview with BioSpace, Imagine Pharma CEO Ngoc Thai shared the vast potential posed by a polypeptide called IMG-1 to treat Type 1 diabetes.
Pfizer is looking to strengthen its grip on mRNA research and development with a $470 million new facility, and Eikon is planning to open a 25,000 facility. Both will be based in New York.
Companies from across the life sciences added new executive and financial leaders, as well as scientific and regulatory additions. Here are this week’s Movers & Shakers.
Freeline Therapeutics’ hemophilia B drug demonstrated the strong possibility that a single injection of FLT180a, an experimental gene therapy, can reduce or eliminate the need for weekly injections.
Assembly Biosciences and X4 Pharmaceuticals have announced significant layoffs and reprioritization endeavors to let go of underperforming initiatives.
Frontera Therapeutics closed on a Series B funding round worth $160 million and announced an IND approval by the FDA for rare genetic retinal disease
The whistleblower claim was brought by former employee Michael Bawduniak, who accused the company of paying off doctors to favor its multiple sclerosis drugs over those of its competitors.
Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.
As Severin Schwan prepares to step aside from the day-to-day leadership of Roche, Thomas Schinecker is waiting in the wings to assume the company’s top leadership spot.